{"id":9639,"date":"2026-05-02T05:50:59","date_gmt":"2026-05-02T10:50:59","guid":{"rendered":"https:\/\/westplexnews.com\/index.php\/2026\/05\/02\/missouri-patients-deserve-transparency-in-the-340b-program-2\/"},"modified":"2026-05-02T05:50:59","modified_gmt":"2026-05-02T10:50:59","slug":"missouri-patients-deserve-transparency-in-the-340b-program-2","status":"publish","type":"post","link":"https:\/\/westplexnews.com\/index.php\/2026\/05\/02\/missouri-patients-deserve-transparency-in-the-340b-program-2\/","title":{"rendered":"Missouri patients deserve transparency in the 340B program"},"content":{"rendered":"
\"Medications
\n

Eric Thayer\/Getty Images).<\/p>\n<\/figcaption><\/figure>\n

The 340B Drug Pricing Program was established with a clear and crucial objective: to assist safety-net providers in efficiently utilizing limited federal resources and expanding healthcare access for vulnerable patients.<\/p>\n

At its core, the 340B program enables eligible healthcare providers to purchase medications at substantial discounts. In return, these providers are expected to utilize the savings to enhance access to care and provide discounted medications to my low-income and underserved neighbors in Missouri.<\/p>\n

However, the law does not mandate that large hospital systems disclose how these savings are utilized. This lack of accountability has created an environment where financial gains can be achieved without providing clear evidence of patient benefit. Consequently, a growing body of evidence suggests that the program has deviated from its original intent. Without meaningful transparency, policymakers, patients, and taxpayers remain unaware of who is genuinely benefiting\u2014and who is not.<\/p>\n

This opacity is no longer a theoretical concern; it is a documented issue. Reports such as Minnesota\u2019s recent 340B analysis have revealed that large hospital systems and for-profit entities often capture significant revenue through the program, while patients themselves experience minimal direct financial relief. Contract pharmacies, their Third-Party Administrators (TPAs), and pharmacy benefit managers (PBMs) have also emerged as major beneficiaries, further complicating the flow of funds and obscuring the ultimate destination of savings.<\/p>\n

My home state of Missouri faces the same challenges.<\/p>\n

Without transparency requirements, it becomes challenging to answer fundamental questions: Are uninsured or underinsured patients receiving discounted medications? Are 340B savings being reinvested into community health programs? How much revenue is being generated\u2014and by whom?<\/p>\n

The absence of answers undermines public trust and weakens the program\u2019s credibility. More importantly, it poses a risk to patients who are being sidelined in a program that was intended to benefit them.<\/p>\n

Meaningful transparency doesn\u2019t mean dismantling the 340B program; it means strengthening it. Missouri lawmakers have an opportunity to lead by implementing common-sense reforms that align the program with its original intent. These reforms should include:<\/p>\n